Form 4 for VTGN Vistagen Therapeutics, Inc.
Accepted 2026-07-02 16:16:44 ET · period of report 2026-06-30 · accession 0001412071-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 16:16 | 2026-06-30 | VTGN | Singh Shawn | Pres, CEO, Dir | A - Grant | $0.1921 | +36.8K | 54.8K | +204% | +$7,073 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | A | A | 36,818 | $0.1921 | 54,846 | D | — | — | (F1) Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP. |